Litcius/Paper detail

Echinacea purpurea polysaccharide intervene in hepatocellular carcinoma via modulation of gut microbiota to inhibit TLR4/NF-κB pathway

Gaoxiang Jing, Wenqian Xu, Wei Ma, Yu Qian, Hongkang Zhu, Chang Liu, Yuliang Cheng, Yahui Guo, He Qian

2024International Journal of Biological Macromolecules31 citationsDOIOpen Access PDF

Abstract

Echinacea purpurea polysaccharide (EPP) exhibit various pharmacological activities, including immunomodulatory, anti-inflammatory, and anti-tumor effects. In this study, we investigated the potential mechanism of EPP intervention in hepatocellular carcinoma (HCC). The results demonstrated that EPP effectively mitigated liver injury caused by HCC, inhibited the proliferation of HCC, and induced apoptosis. Following EPP intervention, there was a significant increase in propionic acid and butyric acid-producing gut microbiota such as Coprococcus, Clostridium and Roseburia, leading to enhanced expression of intestinal tight junction proteins and the repair of the intestinal barrier. This controls lipopolysaccharide (LPS) leakage, which in turn inhibits the TLR4/NF-κB pathway and reduces the expression of inflammatory factors such as IL-6, as well as migration factors like MMP-2. Metabolomics revealed the downregulation of pyrimidine metabolism and nucleotide metabolism, along with the upregulation of butyrate metabolism in tumor cells. This study demonstrated that EPP effectively regulated LPS leakage by modulating gut microbes, and this modulation influenced the TLR4/NF-κB pathway, ultimately disrupting tumor cell survival induced by HCC in mice.

Topics & Concepts

Downregulation and upregulationTLR4RoseburiaGut floraButyrateLipopolysaccharideNF-κBButyric acidHepatocellular carcinomaBiologyApoptosisCancer researchChemistrySignal transductionImmunologyBiochemistryLactobacillusFermentationGeneGut microbiota and healthGinseng Biological Effects and ApplicationsPharmacological Effects of Natural Compounds
Echinacea purpurea polysaccharide intervene in hepatocellular carcinoma via modulation of gut microbiota to inhibit TLR4/NF-κB pathway | Litcius